Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Acalabrutinib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Acalabrutinib as a study intervention. Browse Acalabrutinib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
127
Shown on this page
12
Current sort
Recently updated
Therapy scope
Acalabrutinib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Acalabrutinib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 85–96 of 127 matching trials for Acalabrutinib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 2 Interventional Results available

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

NCT04189952
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma
Interventions
Acalabrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Completed No phase listed Observational

MEOI and HRQoL in CLL Patients Treated With BTKis

NCT04938141
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Fountain Valley, California • Redlands, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

NCT04402138
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Denver, Colorado • New Orleans, Louisiana • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Of The Selective PKC-β Inhibitor MS- 553

NCT03492125
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
Interventions
MS-553, acalabrutinib, venetoclax, Rituximab, obinutuzumab
Drug
Lead sponsor
MingSight Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Ann Arbor, Michigan • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

NCT04630756
View directory record Official record
Conditions
Advanced Haematological Malignancies
Interventions
AZD4573, Acalabrutinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

NCT04419389
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions
APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT
Drug
Lead sponsor
Aprea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Terminated Phase 1 Interventional

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

NCT04477291
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
CG-806
Drug
Lead sponsor
Aptose Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Results available

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526
View directory record Official record
Conditions
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Interventions
Acalabrutinib
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

NCT03788291
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Acalabrutinib, Rituximab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 19, 2026, 4:52 PM EDT
Terminated Phase 2 Interventional Results available

Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

NCT04337827
View directory record Official record
Conditions
Post-transplant Lymphoproliferative Disorder
Interventions
Rituximab, Acalabrutinib, CT scans
Drug · Diagnostic Test
Lead sponsor
Deepa Jagadeesh
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 19, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Preventing Anaphylaxis With Acalabrutinib

NCT05038904
View directory record Official record
Conditions
Food Allergy, Food Allergy Peanut
Interventions
Acalabrutinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 19, 2026, 4:52 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

NCT05205252
View directory record Official record
Conditions
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
Interventions
Tazemetostat, Tafasitamab, Lenalidomide, Acalabrutinib, Daratumumab (Intravenously), Mosunetuzumab, Daratumumab (Subcutaneously), Hyaluronidase-Fihj, Pomalidomide, Dexamethasone 20mg
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Santa Fe, California • Bolivar, Missouri • East Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 19, 2026, 4:52 PM EDT

About this Acalabrutinib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Acalabrutinib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Acalabrutinib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Acalabrutinib.